JP Morgan Chase’s Rubius Therapeutics, Inc RUBY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-2,196
| Closed | – | – | 7501 |
|
|
2022
Q4 | $0 | Sell |
2,196
-3,561
| -62% | -$973 | ﹤0.01% | 7283 |
|
|
2022
Q3 | $2K | Sell |
5,757
-551,112
| -99% | -$413K | ﹤0.01% | 6288 |
|
|
2022
Q2 | $474K | Sell |
556,869
-2,507,630
| -82% | -$4.21M | ﹤0.01% | 4600 |
|
|
2022
Q1 | $16.9M | Sell |
3,064,499
-97,017
| -3% | -$616K | ﹤0.01% | 1915 |
|
|
2021
Q4 | $30.6M | Buy |
3,161,516
+708,647
| +29% | +$9.83M | ﹤0.01% | 1486 |
|
|
2021
Q3 | $43.9M | Buy |
2,452,869
+91,781
| +4% | +$2M | 0.01% | 1249 |
|
|
2021
Q2 | $57.6M | Buy |
2,361,088
+98,589
| +4% | +$2.47M | 0.01% | 1152 |
|
|
2021
Q1 | $60M | Sell |
2,262,499
-324,623
| -13% | -$4.74M | 0.01% | 1083 |
|
|
2020
Q4 | $19.6M | Buy |
2,587,122
+278,848
| +12% | +$1.66M | ﹤0.01% | 1626 |
|
|
2020
Q3 | $11.7M | Buy |
2,308,274
+250,237
| +12% | +$1.33M | ﹤0.01% | 1922 |
|
|
2020
Q2 | $12.3M | Buy |
2,058,037
+884,463
| +75% | +$5.22M | ﹤0.01% | 1732 |
|
|
2020
Q1 | $5.22M | Buy |
1,173,574
+381,422
| +48% | +$2.83M | ﹤0.01% | 2227 |
|
|
2019
Q4 | $7.53M | Buy |
792,152
+49,819
| +7% | +$482K | ﹤0.01% | 2363 |
|
|
2019
Q3 | $5.83M | Buy |
742,333
+65,145
| +10% | +$759K | ﹤0.01% | 2579 |
|
|
2019
Q2 | $10.1M | Buy |
677,188
+72,519
| +12% | +$1.17M | ﹤0.01% | 2101 |
|
|
2019
Q1 | $10.9M | Buy |
604,669
+273,272
| +82% | +$4.19M | ﹤0.01% | 1974 |
|
|
2018
Q4 | $5.33M | Buy |
331,397
+18,421
| +6% | +$336K | ﹤0.01% | 2531 |
|
|
2018
Q3 | $7.51M | Buy |
+312,976
| New | +$7.16M | ﹤0.01% | 2434 |
|
Other funds holding RUBY
AG
SOMRS
BBA
CGL